Sangamo Therapeutics Toekomstige groei

Future criteriumcontroles 2/6

De verwachting is dat Sangamo Therapeutics de winst en omzet met respectievelijk 65.2% en 41.8% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 60.9% per jaar.

Belangrijke informatie

65.2%

Groei van de winst

60.9%

Groei van de winst per aandeel

Biotechs winstgroei	37.2%
Inkomstengroei	41.8%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Good
Laatst bijgewerkt	13 Nov 2024

Recente toekomstige groei-updates

Geen updates

Recent updates

Winst- en omzetgroeiprognoses

LSE:0R1D - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	97	-50	49	59	6
12/31/2025	74	-49	-28	-18	7
12/31/2024	66	-86	-98	-93	2
9/30/2024	52	-135	-117	-114	N/A
6/30/2024	12	-250	-179	-173	N/A
3/31/2024	19	-328	-218	-207	N/A
12/31/2023	176	-258	-246	-225	N/A
9/30/2023	201	-250	-257	-231	N/A
6/30/2023	218	-199	-265	-238	N/A
3/31/2023	241	-127	-258	-231	N/A
12/31/2022	111	-192	-244	-224	N/A
9/30/2022	112	-178	-235	-219	N/A
6/30/2022	114	-172	-241	-225	N/A
3/31/2022	113	-176	-242	-224	N/A
12/31/2021	111	-178	-257	-233	N/A
9/30/2021	109	-181	-209	-185	N/A
6/30/2021	138	-135	-116	-92	N/A
3/31/2021	131	-124	101	120	N/A
12/31/2020	118	-121	155	170	N/A
9/30/2020	147	-76	136	153	N/A
6/30/2020	111	-102	64	81	N/A
3/31/2020	107	-96	-137	-118	N/A
12/31/2019	102	-95	-165	-144	N/A
9/30/2019	74	-118	-206	-164	N/A
6/30/2019	76	-104	-200	-152	N/A
3/31/2019	80	-90	-37	10	N/A
12/31/2018	84	-68	-7	37	N/A
9/30/2018	71	-63	44	60	N/A
6/30/2018	59	-62	N/A	72	N/A
3/31/2018	46	-58	N/A	6	N/A
12/31/2017	37	-55	N/A	11	N/A
9/30/2017	32	-51	N/A	16	N/A
6/30/2017	23	-58	N/A	14	N/A
3/31/2017	19	-72	N/A	-59	N/A
12/31/2016	19	-72	N/A	-66	N/A
9/30/2016	20	-76	N/A	-63	N/A
6/30/2016	25	-66	N/A	-60	N/A
3/31/2016	30	-52	N/A	-52	N/A
12/31/2015	40	-41	N/A	-34	N/A
9/30/2015	45	-31	N/A	-27	N/A
6/30/2015	49	-29	N/A	-19	N/A
3/31/2015	51	-24	N/A	-19	N/A
12/31/2014	46	-26	N/A	-6	N/A
9/30/2014	38	-30	N/A	-5	N/A
6/30/2014	31	-29	N/A	-3	N/A
3/31/2014	28	-27	N/A	0	N/A
12/31/2013	24	-27	N/A	-19	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat 0R1D de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat 0R1D de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat 0R1D de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van 0R1D ( 41.8% per jaar) zal naar verwachting sneller groeien dan de markt UK ( 3.6% per jaar).

Hoge groei-inkomsten: De omzet van 0R1D ( 41.8% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van 0R1D naar verwachting over 3 jaar hoog zal zijn

Sangamo Therapeutics Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

Third quarter 2024 earnings released: EPS: US$0.051 (vs US$0.59 loss in 3Q 2023)

New major risk - Revenue and earnings growth

Sangamo Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024

New major risk - Financial position

Second quarter 2024 earnings released: US$0.18 loss per share (vs US$0.66 loss in 2Q 2023)

Sangamo Therapeutics, Inc. to Report Q2, 2024 Results on Aug 06, 2024

New minor risk - Market cap size

New major risk - Financial position

Sangamo Therapeutics, Inc. Reports Impairment Charges for the First Quarter Ended March 31, 2024

First quarter 2024 earnings released: US$0.27 loss per share (vs US$0.13 profit in 1Q 2023)

Sangamo Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Sangamo Therapeutics, Inc. Receives A Deficiency Notice from Nasdaq

Sangamo Therapeutics, Inc., Annual General Meeting, Jun 04, 2024

New minor risk - Market cap size

Sangamo Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $24 million.

Sangamo Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $24 million.

Sangamo Therapeutics, Inc. Reports Impairment Results for the Fourth Quarter Ended December 31, 2023

Full year 2023 earnings released: US$1.48 loss per share (vs US$1.25 loss in FY 2022)

Sangamo Therapeutics, Inc. to Report Q4, 2023 Results on Mar 13, 2024

Sangamo Therapeutics, Inc. Announces Updated Preliminary Data from the Phase 1/2 STAAR Clinical Study Evaluating Isaralgagene Civaparvovec, or ST-920

Sangamo Therapeutics, Inc Announces Pivotal Readout in the Middle of 2024 for the Phase 3 Affine Trial

Sangamo Therapeutics, Inc. Reports Impairment Charges for the Three Months Ended September 30, 2023

Sangamo Therapeutics, Inc. to Report Q3, 2023 Results on Nov 01, 2023

Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy

New minor risk - Market cap size

New major risk - Financial position

Second quarter 2023 earnings released: US$0.66 loss per share (vs US$0.29 loss in 2Q 2022)

Sangamo Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Sangamo Therapeutics, Inc. Appoints Lisa Rojkjaer as Chief Medical Officer

First quarter 2023 earnings released: EPS: US$0.13 (vs US$0.30 loss in 1Q 2022)

Full year 2022 earnings released: US$1.25 loss per share (vs US$1.23 loss in FY 2021)

Sangamo Therapeutics, Inc. Announces Directors Appointment

Insufficient new directors

Third quarter 2022 earnings released: US$0.34 loss per share (vs US$0.33 loss in 3Q 2021)

Sangamo Therapeutics, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Sangamo Therapeutics, Inc. Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated a-Gal A Enzyme Activity in Nine Patients

Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Clinical Study Showing Continued Tolerability and Sustained Elevated A-Gal A Enzyme Activity in Five Longest Treated Patients

Sangamo Therapeutics, Inc Announces Executive Changes

Second quarter 2022 earnings released: US$0.29 loss per share (vs US$0.33 loss in 2Q 2021)

Sangamo Therapeutics, Inc. to Report Q2, 2022 Results on Aug 04, 2022

First quarter 2022 earnings released: US$0.30 loss per share (vs US$0.32 loss in 1Q 2021)

Sangamo Therapeutics, Inc. to Present Data From Its Next-Generation Technologies at 2022 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

High number of new and inexperienced directors

Saira Ramasastry Decides Not to Stand for Re-Election as A Member of the Board of Directors of Sangamo Therapeutics, Inc

Sangamo Therapeutics, Inc., Annual General Meeting, May 24, 2022

Sangamo Therapeutics, Inc. Announces Dosing of First Patient in Phase 1/2 Clinical Study of Investigational CAR-Treg Cell Therapy TX200 in Kidney Transplantation

Sangamo Therapeutics, Inc. Doses First Patient in Its Phase 1/2 STEADFAST Clinical Study Evaluating TX200

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Sangamo Therapeutics, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Sangamo Therapeutics, Inc. Announces Updated Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated A-Gal A Enzyme Activity in Patients with Fabry Disease

Sangamo Therapeutics Announces Updated Preliminary SAR445136 Phase 1/2 Proof-of-Concept Data Showing Tolerability and Sustained Effects in Sickle Cell Disease

Third quarter 2021 earnings released: US$0.33 loss per share (vs US$0.011 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.33 loss per share (vs US$0.26 loss in 2Q 2020)

First quarter 2021 earnings released: US$0.32 loss per share (vs US$0.37 loss in 1Q 2020)

Executive VP recently sold US$73k worth of stock

Sangamo Therapeutics, Inc. Appoints Prathyusha Duraibabu as Principal Financial Officer

Full year 2020 earnings released: US$0.90 loss per share (vs US$0.85 loss in FY 2019)

Revenue misses expectations

Sangamo Therapeutics, Inc. to Report Q4, 2020 Results on Feb 24, 2021

Executive VP & CFO has left the company

Sangamo Therapeutics Appoints Rob Schott as Senior Vice President and Head of Development

Sangamo Therapeutics Announces Departure of Chief Financial Officer Sung Lee, Effective February 1, 2021

Insider recently sold US$60k worth of stock

Third quarter 2020 earnings released: US$0.011 loss per share

Revenue beats expectations

Sangamo Therapeutics, Inc. to Report Q3, 2020 Results on Nov 04, 2020

Pfizer Inc. and Sangamo Therapeutics, Inc. Dose First Participant in Phase 3 Study Evaluating Hemophilia A Gene Therapy Treatment

Sangamo Therapeutics, Inc. Announces Upcoming Clinical Data Presentations At WORLDSymposium 2019

Sangamo BioSciences, Inc. has entered into a definitive asset purchase agreement to acquire angiogenesis program from and Edwards Lifesciences Corporation for $7.5 million.

First half earnings released

Sangamo Therapeutics, Inc.(NasdaqGS:SGMO) dropped from Russell Small Cap Comp Value Index

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen